Jove
Visualize
Contact Us

Related Experiment Videos

Bromocriptine in pregnancy: safety aspects.

P Krupp1, C Monka

  • 1Drug Monitoring Centre, Clinical Research, Sandoz, Basle, Switzerland.

Klinische Wochenschrift
|September 1, 1987
PubMed
Summary

Bromocriptine treatment for infertility in hyperprolactinemic women is safe during pregnancy. It does not increase risks for miscarriage, multiple births, birth defects, or impact child development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.

Cephalalgia : an international journal of headache·2001
Same author

Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.

Archives of dermatology·1997
Same author

Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun.

Transplantation proceedings·1997
Same author

Agranulocytosis and clozapine.

BMJ (Clinical research ed.)·1994
Same author

Acute overdosage with Sandimmun: the influence of dose and patients' underlying condition.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·1994
Same author

Long-term safety of cyclosporine in renal transplant recipients: worldwide experience.

Transplantation proceedings·1993
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology
  • Pediatric Development

Background:

  • Hyperprolactinemia often impairs fertility in women.
  • Bromocriptine is a dopamine agonist used to treat hyperprolactinemia and restore fertility.

Purpose of the Study:

  • To investigate the safety of Bromocriptine use during pregnancy.
  • To assess the impact of in utero Bromocriptine exposure on offspring development.

Main Methods:

  • A stepwise approach involving spontaneous reporting, intensive monitoring across 33 clinics, and comprehensive child examinations up to age 9.
  • Data collected from 2587 pregnancies and follow-up on 988 infants exposed to Bromocriptine.

Main Results:

  • No increased risk of spontaneous abortion, multiple pregnancy, or congenital malformations observed.
  • Bromocriptine exposure in utero showed no adverse effects on postnatal development.

Conclusions:

  • Bromocriptine is a safe treatment option for infertility associated with hyperprolactinemia.
  • In utero exposure to Bromocriptine does not pose risks to pregnancy outcomes or child development.

Related Experiment Videos